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Screens
Strengths
• Quick to administer
• Less skill/training administration
• Easy to interpret – pass/fail
• More tolerable – fatigue/effort
Consequences
• Not necessarily neuropsychology
• Expedite/screen referrals
• More patients to be seen
• Targeted formal batteries
Formal
Difficulties
• Training in administration
• Skill in interpretation
• Time/Resources
• Prolonged period of 
effort/engagement
Consequences
• Less patients seen
• Potential delay in the detection of 
impairment
SCREENING TOOLS VERSUS FORMAL ASSESSMENT
SCREENING TOOLS WELL ESTABLISHED IN ADULT
POPULATIONS
HARDER FOR KIDS…
• Psychometrically more 
complicated
• Sensitive to developmental 
gains
• Avoid floor/Ceiling effects
Our objectives
• Design screening tool for use with school age children (5-16 years)
• Quick and easy to administer
• Cover wide range of domains:
• language, fluency, memory, attention, visuospatial function
• Provide normative data
• Provide an assessment of its validity within a clinical setting based on 
a small preliminary sample.
• Stratified into two age bands (5-11; 12-16) to reduce floor/ceiling 
effects
THE CCOSI – PRELIMINARY STUDY
THE MEASURE
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METHOD
Participants
• 240 typically developing children (mean age = 10:07) 
• 17 patients collected so far (14:09)
• 14 analysed for sensitivity and specificity (mean age = 11:06)
Procedure
• Association between age and scores on each cognitive 
domain of the CCoSI were analysed
• Patient results were compared to standardised 
neuropsychological tests in order to assess validity
• Sensitivity and specificity of total scores were examined 
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Figure 1. Median scores on each CCoSI domain for each age. Values reported for 12-15 year olds are for scores on the CCoSI-II and cannot 
be directly compared to all other ages, who completed the CCoSI-I. Scores on each domain have different maximum values (Attention = 
21; Fluency = 14; Memory = 19; Language = 35; Visuospatial = 15). 
PATIENT DEMOGRAPHIC DATA
Age Gender Diagnosis/Pathology
TBI (n = 3) 12y 6m Female Head injury
15y 5m Male Head injury
14y 11m Male Head injury
Epilepsy (n = 6) 10y 1m Male Landau-Kleffner
16y 9m Female Epilepsy 
17y 10m Female Left sided hemispherotomy /Epilepsy
12y 5m Male Epilepsy 
11y 0m Female Epilepsy 
16y 9m Male Epilepsy 
Inflammatory (n = 1) 16y 8m Female Anti-NMDA receptor Encephalitis
Neoplastic (n = 2) 15y 6m Female Retro-pharyngeal Ewing's sarcoma
16y 1m Male Pontine carvenoma
CVA (n = 1) 10y m1 Female Left frontal arteriovenous malformation and 
subsequent haemorrhage
Other (n = 4) 16y 2m Female Asymmetric venrtriculomegaly
15y 5m Female Migraine
7y 7m Male Rhombencephalosynapsis
15y 10m Male Spina Bifida
PATIENT PERFORMANCE DATA COMPARED TO HEALTHY CONTROLS
PATIENT SENSITIVITY AND SPECIFICITY DATA
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RESULTS (PATIENT DATA)
Domain 5th Percentile 10
th Percentile 15th Percentile 
TP TN FP FN % error TP
T
N FP
F
N % error T   P
T
N FP FN % error
Attention 1 5 2 0 25.0 1 4 3 0 37.5 1 4 3 0 37.5
Fluency 0 6 2 0 25.0 0 5 3 0 37.5 0 4 4 0 50.0
Memory 1 4 1 2 37.5 2 4 1 1 25.0 2 3 2 1 37.5
Language 3 5 0 0 0.0 3 4 1 0 12.5 3 4 1 0 12.5
Visuospatial 1 5 2 0 25.0 1 3 4 0 50.0 1 3 4 0 50.0
Note. % error displays percentage of false classifications. TP = true positive; TN = true
negative; FP = false positive; FN = false-negative.
• 5th percentile threshold produces lowest error percentage 
for majority of domains but results in additional FN 
compared to 10th percentile
Domain 
Threshold Cut-Off Sensitivity (%) Specificity (%) PPV (%) NPV (%)
5th Percentile
≥2
100.0
(39.8-100.0)
100.0
(39.8-100.0)
100.0
(39.8-100.0)
100.0
(39.8-100.0)
≥3
50.0
(6.8-93.2)
100.0
(39.8-100.0)
100.0
(15.8-100.0)
66.7
(22.3-95.7)
10th Percentile
≥2
100.0
(39.8-100)
25.0
(0.6-80.6)
57.1
(18.4-90.1)
100.0 
(2.5 – 100.0)
≥3
75.0
(19.4-99.4)
75.0
(19.4-99.4
75.0
(19.4-99.4)
75.0
(19.4-99.4)
• Total scored based on 5th percentile domain threshold and 
a cut-off of ≥2 has greatest sensitivity and specificity of 
100% 
RESULTS (PATIENT DATA)
DISCUSSION – RESULTS SUMMARY
• Total score based on 5th percentile domain threshold can 
detect cognitive impairments 
• 5th percentile domain threshold able to provide indication of 
which domains require further assessment
• 5th percentile more specific threshold, 10th percentile more 
sensitive 
• Domain scores calculated first to provide indication of 
whether further assessment needed
• Domain scores used to guide test selection – threshold 
choice for cut-off determined by clinical need
• Help early detection of cognitive problems and prevents 
unnecessary assessment
DISCUSSION – CLINICAL APPLICATIONS
DISCUSSION – LIMITATIONS AND FUTURE RESEARCH
Limitations
• Small sample size –
• only 17 patients with heterogeneous diagnoses
• Ceiling effects with current cut-offs
Future research
• Find the ‘sweet spot’
• Individual domain cut-offs with sensitivity and specificity data
• Improved ‘gold standard’ data
• Increase normative and clinical sample
• Assess validity of CCoSI in other settings (e.g. 
school/community settings) and for differing levels of 
impairment or diagnoses
